FDA awards Perspectum major grant for the qualification of its noninvasive diagnostic biomarker to reduce liver biopsy in drug trials
September 27, 2022
LiverMultiScan shown to be a cost-effective alternative to liver biopsies for monitoring patients with autoimmune hepatitis
September 21, 2022
FDA Grants Clearance to Perspectum’s CoverScan – A New Platform-Based Tool to Assess Multiple Organs in One MRI Scan
May 22, 2022
LiverMultiScan® detected earlier stages of treatable disease in patients with autoimmune hepatitis to allow tailored treatment
March 21, 2022
LiverMultiScan® has achieved nationwide payer coverage for diagnosis and management of NAFLD and other established chronic liver diseases
March 14, 2022
First patient recruited for multi-year collaborative primary sclerosing cholangitis (PSC) pediatric study using Perspectum’s imaging technology to help predict disease progression and guide patient management
January 27, 2022
New meta-analysis finds Perspectum’s non-invasive MRI biomarker cT1 is an effective alternative to biopsy for identifying patients at high risk of liver disease progression
January 12, 2022
Perspectum and HepQuant Announce Partnership to Bring a More Complete Picture of Liver Health
November 1, 2021
Perspectum Expands into Louisiana in Partnership with West Jefferson Medical Center in New Orleans, LA
October 5, 2021
